<code id='B9A1CB98D6'></code><style id='B9A1CB98D6'></style>
    • <acronym id='B9A1CB98D6'></acronym>
      <center id='B9A1CB98D6'><center id='B9A1CB98D6'><tfoot id='B9A1CB98D6'></tfoot></center><abbr id='B9A1CB98D6'><dir id='B9A1CB98D6'><tfoot id='B9A1CB98D6'></tfoot><noframes id='B9A1CB98D6'>

    • <optgroup id='B9A1CB98D6'><strike id='B9A1CB98D6'><sup id='B9A1CB98D6'></sup></strike><code id='B9A1CB98D6'></code></optgroup>
        1. <b id='B9A1CB98D6'><label id='B9A1CB98D6'><select id='B9A1CB98D6'><dt id='B9A1CB98D6'><span id='B9A1CB98D6'></span></dt></select></label></b><u id='B9A1CB98D6'></u>
          <i id='B9A1CB98D6'><strike id='B9A1CB98D6'><tt id='B9A1CB98D6'><pre id='B9A1CB98D6'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:4558
          US Capitol - SOTU
          Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

          WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

          It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

          advertisement

          Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more
          Readout Newsletter: BridgeBio, Akero, and human embryo models
          Readout Newsletter: BridgeBio, Akero, and human embryo models

          WellcomeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletteri

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Medicare drug price negotiation hearing pits pharma v Biden admin

          AdobeTRENTON,N.J.—PharmaindustrygiantsincludingBristolMyersSquibb,Johnson&Johnson,Novartis,andNo